On Wednesday, Dicks Sporting Goods Inc (NYSE:DKS)’s shares declined -0.89% to $52.90.
Dicks Sporting Goods Inc (DKS) the largest U.S.-based, full-line omni-channel sporting goods retailer, will be opening its 34th store in Florida and 616th store nationwide on Friday, June 19th at the Florida Mall in Orlando, FL (8001 South Orange Blossom Trail).
DICK’S three-day grand opening celebration will run through Sunday, June 21st. The store will open at 8:00 a.m. Friday and Saturday and 9:00 a.m. Sunday.
On Friday, the first 100 people in line will be eligible for a free Reebok Play Dry® T-Shirt. Guests who are in line at 7:45am on Friday will get a chance to open the DICK’S Sporting Goods Gift Locker.*
Customers can also get tips from a professional angler at the 4,000-gallon DICK’S bass tank on Friday and Saturday from 11:00 a.m. to 7:00 p.m. and Sunday from 11:00 a.m. to 5:00 p.m.
Saturday and Sunday giveaways comprise a free Mystery Gift Card from $5 to $500 for the first 100 adults in line. Guests who are in line at 7:45 a.m. Saturday and 8:45 a.m. on Sunday will also get a chance to open the DICK’S Sporting Goods Gift Locker.*
Dick’s Sporting Goods, Inc. operates as a sporting goods retailer primarily in the eastern United States. The company provides hardlines, counting sporting goods equipment, fitness equipment, golf equipment, and hunting and fishing gear products; apparel; and footwear products and accessories.
Principal Financial Group Inc (NYSE:PFG)’s shares gained 1.88% to $52.64.
Principal Financial Group Inc (PFG) continues to benefit from fee-based businesses. Operating net income of $1.09 per share in the first quarter outperformed the Zacks Consensus Estimate and improved year over year. The quarter marked the second-highest quarterly earnings per share. With respect to earnings, this Zacks Rank #3 (Hold) company recorded a positive surprise in each of the last four quarters, with an average beat of 6.95%.
While a sturdy investment performance and distribution relationships drove sales, asset under administration (AUM) were a record $530.3 billion.
Deeper focus on fee-based revenue sources (anticipates 70% coming from it by 2018) has been assisting the company to earn steadily, besides limiting exposure to the interest rate environment. Riding on this strength, the company plans $0.8–$1 billion in capital deployment in 2015.
Principal Financial’s inorganic growth story seems attractive with the prudent acquisitions it makes. Its latest acquisitions of AXA’s Mandatory Provident Fund (MPF) and the Occupational Retirement Schemes Ordinance pension business in Hong Kong are predictable to close in the second half of 2015. The buyout will more than double the AUM of its Hong Kong pension business to over US $6 billion and will be ranked as the fifth largest MPF provider in that market. Since being hit by the financial crisis, it has made nine acquisitions, adding fee-based businesses and expanding its global footprint.
Principal Financial Group, Inc. provides retirement, asset administration, and insurance products and services. It operates through Retirement and Investor Services, Principal Global Investors, Principal International, and U.S. Insurance Solutions segments.
At the end of Wednesday’s trade, OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI)‘s shares surged 7.31% to $2.79.
OncoGenex Pharmaceuticals Inc (OGXI) declared that the U.S. Food and Drug Administration (FDA) has agreed to the Company’s projected amendment to the Phase 3 AFFINITY protocol and statistical analysis plan. The amendment comprises the addition of a co-primary endpoint designed to prospectively evaluate the survival benefit of custirsen in men who are at raised risk for poor outcomes when treated with cabazitaxel for metastatic castrate-resistant prostate cancer (CRPC).
The FDA is in agreement with plans for prospectively defining a poor prognostic subpopulation in the Phase 3 AFFINITY trial. OncoGenex, in partnership with study investigators, has defined a simple 5-criteria characterization for poor prognosis in prostate cancer based on the Phase 3 SYNERGY trial, which comprises: poor performance status, elevated prostate specific antigen (PSA), elevated lactate dehyrdogenase (LDH), reduced hemoglobin, and the presence of liver metastasis. Patients with poor prognosis will be identified as having 2 or more of these 5 well-recognized high-risk criteria. The projected change for AFFINITY also comprises with custirsen’s mechanism of action, since custirsen was designed to address treatment resistance which may be more prevalent in this subpopulation.
In the revised statistical analysis plan for the AFFINITY trial, the hypothesized hazard ratio (HR) for the poor prognosis subpopulation is specified to be 0.69 with the critical HR ≤ 0.778. The hypothesized HR for the intent-to-treat patients (ITT population) remains unchanged as 0.75 with the critical HR ≤ 0.820.
OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. The company’s product candidates comprise Custirsen that is in Phase III clinical development for the treatment in men with metastatic castrate-resistant prostate cancer, in addition to in patients with non-small cell lung cancer; and Apatorsen, which is in two Phase I and seven randomized Phase II trials for the treatment of bladder, lung, pancreatic, and prostate cancers.
Triangle Petroleum Corporation (NYSEMKT:TPLM), ended its Wednesday’s trading session with 4.93% gain, and closed at $5.32.
Triangle Petroleum Corporation (TPLM) provides an operational update and reports its first quarter fiscal year 2016 financial results for the three-month period ended April 30, 2015 (“Q1 fiscal 2016″ or “Q1 FY 2016″).
First Quarter Highlights for Fiscal Year 2016 (ended April 30, 2015)
- Quarterly production volumes of ~1,226 Mboe (13,775 Boepd)
- Increasing full fiscal year 2016 production guidance to a range of 11,500-13,500 Boepd
- No change to formerly issued capital expenditure guidance
- Further enhances to production guidance will be considered as fiscal year 2016 progresses
- Triangle USA Petroleum (“TUSA”) driving continued reduction in drilling and completion costs
- Leading edge AFEs $7.3 million as of May 2015
- Merged cash flow from operations (before working capital changes) of $31.4 million, or $0.42 per fully diluted share; Operating cash flow of $39.3 million
- 23% quarter over quarter decrease in merged cash general and administrative expenses
- Merged adjusted revenue of $137.8 million counting $19.5 million of cash receipts from hedge settlements
Segment Operational Update
- TUSA generated $47.8 million of revenue in Q1 FY 2016 not taking into account $19.5 million of cash receipts from hedge settlements as contrast to $60.8 million of revenue in Q1 FY 2015 (-21% y/y). The contribution from year over year production growth partially offset a 54% drop in average pre-hedge realized prices to $38.97/Boe from $84.08/Boe
- Based on realized commodity prices in the month of May, current futures prices, and recent differentials, Q2 FY 2016 pre-hedge realized prices per Boe are trending 20% higher sequentially from Q1 FY 2016 actual pre-hedge realized prices of $38.97/Boe
- Spud 10 gross (7.3 net) and accomplished 5 gross (3.3 net) operated wells with a two-rig operated program in Q1 FY 2016
- Total of 23 gross (18.7 net) operated wells either in progress or waiting on completion as of April 30, 2015
Triangle Petroleum Corporation, an independent energy company, explores for, develops, and produces oil and natural gas resources primarily in the Bakken Shale and Three Forks formations in the Williston Basin of North Dakota and Montana. The company operates through Exploration and Production, and Oilfield Services segments. As of January 31, 2015, it held leasehold interests in about 126,037 net acres in the Williston Basin of North Dakota and Montana.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
